K161817 is an FDA 510(k) clearance for the Tina-quant Cystatin C Gen.2. Classified as Test, Cystatin C (product code NDY), Class II - Special Controls.
Submitted by Roche Diagnostics Operations (Rdo) (Indianapolis, US). The FDA issued a Cleared decision on July 27, 2016 after a review of 26 days - a notably fast clearance cycle.
This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1225 - the FDA in vitro diagnostics and chemistry framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.
Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.